Analysts expect the partners’ first-mover advantage, clinical data and existing presence in lung disease to translate into ...

GSK plc (LSE/NYSE: GSK) has released new data from the AReSVi-006 Phase III trial, demonstrating the efficacy and safety of ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

Artificial intelligence chatbots cannot be relied on to give accurate, safe or even clear advice about medication, according ...

GSK announced another batch of positive data from its respiratory program with the investigational drug depemokimab, this ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

GSK Plc’s experimental drug to treat a common inflammatory nasal condition showed positive results in two late-stage trials ...

GSK said its depemokimab respiratory drug met the main objectives in two late-stage clinical trials, showing efficacy for the treatment of chronic rhinosinusitis with nasal polyps.

Uncertainty around the event and suspected tax changes in the upcoming budget has left many investors in the dark.

The artificial intelligence (AI) market has created some monster growth stocks already, but companies involved in enabling this technological revolution are still seeing growing opportunities. Here ...

In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...